GSK, Nuvalent aim to agree a deal as soon as this week: FT

Nuvalent, Inc. (Nasdaq: NUVL) is currently in advanced discussions with GlaxoSmithKlein (GSK), with the Financial Times reporting that a potential deal could be finalized as soon as this week. The biopharmaceutical company has been making significant strides in its pipeline of targeted therapies for non-small cell lung cancer (NSCLC), particularly in the areas of ROS1- and ALK-positive indications.

Nuvalent recently announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for neladalkib for the treatment of tyrosine kinase inhibitor (TKI) pre-treated advanced ALK-positive NSCLC under Priority Review, with a PDUFA target action date of November 27, 2026. Additionally, the NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC has also been accepted by the FDA, with a PDUFA date of September 18, 2026.

The company has also expanded its leadership team, with Georg Pirmin Meyer, M.D., joining as Chief International Officer to lead global expansion efforts. Nuvalent’s financial position remains strong, with approximately $1.4 billion in cash, cash equivalents, and marketable securities as of the end of 2025, providing operating runway into 2029.

With multiple potential regulatory milestones on the horizon and a robust financial position, Nuvalent is well-positioned for strategic partnerships or acquisitions, making the reported discussions with GSK a significant development for the company and its stakeholders.